200 related articles for article (PubMed ID: 25814555)
1. Systematic analysis of BRAF(V600E) melanomas reveals a role for JNK/c-Jun pathway in adaptive resistance to drug-induced apoptosis.
Fallahi-Sichani M; Moerke NJ; Niepel M; Zhang T; Gray NS; Sorger PK
Mol Syst Biol; 2015 Mar; 11(3):797. PubMed ID: 25814555
[TBL] [Abstract][Full Text] [Related]
2. Combinatorial drug screening and molecular profiling reveal diverse mechanisms of intrinsic and adaptive resistance to BRAF inhibition in V600E BRAF mutant melanomas.
Roller DG; Capaldo B; Bekiranov S; Mackey AJ; Conaway MR; Petricoin EF; Gioeli D; Weber MJ
Oncotarget; 2016 Jan; 7(3):2734-53. PubMed ID: 26673621
[TBL] [Abstract][Full Text] [Related]
3. COT drives resistance to RAF inhibition through MAP kinase pathway reactivation.
Johannessen CM; Boehm JS; Kim SY; Thomas SR; Wardwell L; Johnson LA; Emery CM; Stransky N; Cogdill AP; Barretina J; Caponigro G; Hieronymus H; Murray RR; Salehi-Ashtiani K; Hill DE; Vidal M; Zhao JJ; Yang X; Alkan O; Kim S; Harris JL; Wilson CJ; Myer VE; Finan PM; Root DE; Roberts TM; Golub T; Flaherty KT; Dummer R; Weber BL; Sellers WR; Schlegel R; Wargo JA; Hahn WC; Garraway LA
Nature; 2010 Dec; 468(7326):968-72. PubMed ID: 21107320
[TBL] [Abstract][Full Text] [Related]
4. Mutant BRAF melanomas--dependence and resistance.
Poulikakos PI; Rosen N
Cancer Cell; 2011 Jan; 19(1):11-5. PubMed ID: 21251612
[TBL] [Abstract][Full Text] [Related]
5. KDM5B Promotes Drug Resistance by Regulating Melanoma-Propagating Cell Subpopulations.
Liu X; Zhang SM; McGeary MK; Krykbaeva I; Lai L; Jansen DJ; Kales SC; Simeonov A; Hall MD; Kelly DP; Bosenberg MW; Yan Q
Mol Cancer Ther; 2019 Mar; 18(3):706-717. PubMed ID: 30523048
[TBL] [Abstract][Full Text] [Related]
6. Vemurafenib Limits Influenza A Virus Propagation by Targeting Multiple Signaling Pathways.
Holzberg M; Boergeling Y; Schräder T; Ludwig S; Ehrhardt C
Front Microbiol; 2017; 8():2426. PubMed ID: 29312159
[TBL] [Abstract][Full Text] [Related]
7. Highly multiplexed imaging of single cells using a high-throughput cyclic immunofluorescence method.
Lin JR; Fallahi-Sichani M; Sorger PK
Nat Commun; 2015 Sep; 6():8390. PubMed ID: 26399630
[TBL] [Abstract][Full Text] [Related]
8. Fractional killing arises from cell-to-cell variability in overcoming a caspase activity threshold.
Roux J; Hafner M; Bandara S; Sims JJ; Hudson H; Chai D; Sorger PK
Mol Syst Biol; 2015 May; 11(5):803. PubMed ID: 25953765
[TBL] [Abstract][Full Text] [Related]
9. Adaptive resistance of melanoma cells to RAF inhibition via reversible induction of a slowly dividing de-differentiated state.
Fallahi-Sichani M; Becker V; Izar B; Baker GJ; Lin JR; Boswell SA; Shah P; Rotem A; Garraway LA; Sorger PK
Mol Syst Biol; 2017 Jan; 13(1):905. PubMed ID: 28069687
[TBL] [Abstract][Full Text] [Related]
10. Surviving apoptosis: life-death signaling in single cells.
Flusberg DA; Sorger PK
Trends Cell Biol; 2015 Aug; 25(8):446-58. PubMed ID: 25920803
[TBL] [Abstract][Full Text] [Related]
11. Growth rate inhibition metrics correct for confounders in measuring sensitivity to cancer drugs.
Hafner M; Niepel M; Chung M; Sorger PK
Nat Methods; 2016 Jun; 13(6):521-7. PubMed ID: 27135972
[TBL] [Abstract][Full Text] [Related]
12. Drug-induced adverse events prediction with the LINCS L1000 data.
Wang Z; Clark NR; Ma'ayan A
Bioinformatics; 2016 Aug; 32(15):2338-45. PubMed ID: 27153606
[TBL] [Abstract][Full Text] [Related]
13. Reduced-representation Phosphosignatures Measured by Quantitative Targeted MS Capture Cellular States and Enable Large-scale Comparison of Drug-induced Phenotypes.
Abelin JG; Patel J; Lu X; Feeney CM; Fagbami L; Creech AL; Hu R; Lam D; Davison D; Pino L; Qiao JW; Kuhn E; Officer A; Li J; Abbatiello S; Subramanian A; Sidman R; Snyder E; Carr SA; Jaffe JD
Mol Cell Proteomics; 2016 May; 15(5):1622-41. PubMed ID: 26912667
[TBL] [Abstract][Full Text] [Related]
14. A Phosphoproteomic Comparison of B-RAFV600E and MKK1/2 Inhibitors in Melanoma Cells.
Stuart SA; Houel S; Lee T; Wang N; Old WM; Ahn NG
Mol Cell Proteomics; 2015 Jun; 14(6):1599-615. PubMed ID: 25850435
[TBL] [Abstract][Full Text] [Related]
15. The Novel ATP-Competitive MEK/Aurora Kinase Inhibitor BI-847325 Overcomes Acquired BRAF Inhibitor Resistance through Suppression of Mcl-1 and MEK Expression.
Phadke MS; Sini P; Smalley KS
Mol Cancer Ther; 2015 Jun; 14(6):1354-64. PubMed ID: 25873592
[TBL] [Abstract][Full Text] [Related]
16. Combining BRAF(V) (600E) inhibition with modulators of the mitochondrial bioenergy metabolism to overcome drug resistance in metastatic melanoma.
Livingstone E; Swann S; Lilla C; Schadendorf D; Roesch A
Exp Dermatol; 2015 Sep; 24(9):709-10. PubMed ID: 25865258
[No Abstract] [Full Text] [Related]
17. Inhibition of vemurafenib-resistant melanoma by interference with pre-mRNA splicing.
Salton M; Kasprzak WK; Voss T; Shapiro BA; Poulikakos PI; Misteli T
Nat Commun; 2015 May; 6():7103. PubMed ID: 25971842
[TBL] [Abstract][Full Text] [Related]
18. The nuclear translocation of ERK1/2 as an anticancer target.
Plotnikov A; Flores K; Maik-Rachline G; Zehorai E; Kapri-Pardes E; Berti DA; Hanoch T; Besser MJ; Seger R
Nat Commun; 2015 Mar; 6():6685. PubMed ID: 25819065
[TBL] [Abstract][Full Text] [Related]
19. Inducible but not constitutive expression of PD-L1 in human melanoma cells is dependent on activation of NF-κB.
Gowrishankar K; Gunatilake D; Gallagher SJ; Tiffen J; Rizos H; Hersey P
PLoS One; 2015; 10(4):e0123410. PubMed ID: 25844720
[TBL] [Abstract][Full Text] [Related]
20. The c-Jun/RHOB/AKT pathway confers resistance of BRAF-mutant melanoma cells to MAPK inhibitors.
Delmas A; Cherier J; Pohorecka M; Medale-Giamarchi C; Meyer N; Casanova A; Sordet O; Lamant L; Savina A; Pradines A; Favre G
Oncotarget; 2015 Jun; 6(17):15250-64. PubMed ID: 26098773
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
